Foreign Media: Analysts say China is poised to produce a domestic pharmaceutical company capable of rivaling global giants within the next decade. At the Hong Kong Global Health Summit, the founder of CBC Group stated that for the past three decades, there was only one drug research and development ecosystem in the world—America's. However, over the past ten years, China has emerged as the second major system running parallel to it. China’s advantages extend beyond lower costs; they also include faster R&D speed, and this efficiency advantage is irreversible.
Nevertheless, he pointed out that the biopharmaceutical industry differs from other sectors—it requires years of regulatory approval, a deep pipeline of hundreds of new drugs, and accumulation of next-generation technologies before achieving substantial market impact. Therefore, building Chinese pharmaceutical companies with global competitiveness will remain a long-term process.
Original article: toutiao.com/article/1873148138797056/
Disclaimer: The views expressed in this article are solely those of the author.